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Synopsis 
 
 
 
 
Vps13 proteins have a prominent contribution to human health and disease, although their function is 
obscured. Studies using simple eukaryotes greatly extended the knowledge about Vps13 proteins, 
indicated their role in actin cytoskeleton, vesicular trafficking, regulation of membrane contact sites, 
mitochondrial functioning and autophagy, and allow to classify the yeast Vps13 as a lipid-binding 
protein. Moreover, these studies revealed the pathogenic mechanism of the mutations found in 
VPS13-associated neurodegenerative disorder Chorea-acanthocytosis. Recent findings in the field are 
presented and discussed. 
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Abstract 
Human Vps13 proteins are associated with 
several diseases, including the neurodegenerative 
disorder Chorea-acanthocytosis (ChAc). However, 
the biology of these proteins is relatively poorly 
understood. Studies in lower eukaryotic models, 
such as Saccharomyces cerevisiae and 
Dictyostelium discoideum, point to the involvement 
of Vps13 in many key cellular processes, the actin 
cytoskeleton organization, vesicular trafficking, 
regulation of membrane contact sites, mitochondrial 
functioning and autophagy. Recent findings 
revealed that yeast Vps13 binds 
phosphatidylinositol lipids via at least four different 
lipid binding regions. Modelling of ChAc-associated 
mutations in yeast has revealed that particular 
amino acid substitutions give rise to specific 
phenotypes. Noteworthy, a mutation in the APT1 
domain of Vps13 results in diminished lipid binding 
and disturbances of all processes studied, including 
the actin cytoskeleton organization, vacuolar 
transport, endocytosis and sporulation. This review 
describes the great potential of simple eukaryotes to 
decipher disease mechanisms and highlights novel 
insights into the pathological role of Vps13 towards 
ChAc. 
 
Introduction 
There are growing evidences that members 
of the human Vps13 protein family have a prominent 
contribution in health and disease [1]. Defects in the 
expression and structure of all human hVPS13 
genes are linked to multiple disorders, such as 
neurodegeneration and neurological diseases, 
cancers and diabetes. In particular, mutations in 
hVPS13A gene lead to a complex and fatal disease 
known as Chorea-acanthocytosis [2]. Despite their 
relevance, the functioning of Vps13 proteins in cells 
and their molecular role in particular cellular 
processes are still unclear. In the last years, an 
increasing number of studies have taken advantage 
of simple experimental models to deeply investigate 
the function of Vps13 proteins. In this review we 
summarize the recent reports regarding the domain 
structure and functions of Vps13 proteins, and 
modelling of mutations found in ChAc disease, 
especially focusing on the simple eukaryote 
Saccharomyces cerevisiae. Other experimental 
models such as Tetrahymena thermophila, 
Dictyostelium discoideum and Drosophila 
melanogaster are also contributing to understand 
the complexity of Vps13 proteins. These studies 
have revealed potential pathways affected in the 
diseases, which include actin cytoskeleton 
organization, vesicle trafficking, regulation of 
membrane contact sites between organelles, 
mitochondrial function, phagocytosis and 
autophagy. Modelling of diseases in simple 
eukaryotes can shed more light into the pathological 
mechanisms and may serve as experimental 
platforms for drug testing. 
 
Human diseases associated with VPS13 genes 
In the human genome, there are four widely 
expressed genes: hVPS13A, hVPS13B, hVPS13C 
and hVPS13D encoding hVPS13 proteins (here 
referred to as hVps13, for clarity) [1]. Mutations or 
alternations in the expression of these genes are 
associated with various human disorders (Table 1). 
Mutations in hVPS13A lead to the rare hereditary 
disease – Chorea-acanthocytosis (ChAc; OMIM 
200150) [2–4], an autosomal recessive disorder 
characterized by adult-onset chorea, progressive 
neurodegeneration and abnormal erythrocyte 
morphology – acanthocytosis [5]. Mutations in 
hVPS13B cause Cohen syndrome (OMIM 216550) 
[6], a rare autosomal recessive disorder 
characterized by non-progressive psychomotor 
retardation, microcephaly, characteristic facial 
features, retinal dystrophy, and intermittent 
neutropenia in children [7], but there are also 
reports of correlation with autism and other 
neurological disorders (Table 1). In turn, hVPS13C 
mutations are implicated in a distinct form of early-
onset Parkinsonism (OMIM 616840) characterized 
by rapid and severe disease progression and early 
cognitive decline [8]. Genetic studies have also 
revealed that variants of hVPS13C are associated 
with increased risk of diabetes [9–12]. On the other 
hand, it was identified a genetic variation in the 
hVPS13D allele, which contributes to septic shock 
mortality [13]. There are also reports of putative 
associations of hVPS13A, hVPS13C and hVPD13D 
variations with schizophrenia [14,15]. Finally, 
alterations in the expression level and/or mutations 
in all human hVPS13 are found in some cancers 
[16–21].  
 
The complex roles of Vps13 proteins in 
mammalian cells  
Despite the obvious fact that human hVPS13 
genes are involved in several disorders, little is still 
known about the role of hVps13 proteins in cells and 
their exact molecular function(s). The most studied 
member of hVps13 protein family, hVps13A, is 
apparently involved in cytoskeletal structure 
organization and dynamics, such as actin filaments 
[22–26], microtubule and intermediate filament 
(desmin and cytokeratin) networks [27]. It also 
regulates vesicular transport [22,79], autophagy [28] 
and is involved in the metabolism of 
phosphoinositides (PIPs) [29]. The hVps13B is a 
peripheral membrane protein localized to the Golgi 
complex, required for maintenance of the Golgi 
complex morphology [30] and essential for normal 
glycosylation of proteins [31]. The hVps13C protein 
is enriched in the outer membrane of mitochondria 
[8], lipid droplets (LD) [32] and, based on cell 
fractionation studies, in early endosomes (EE) [8]. 
The hVps13C seems to be involved in maintenance 
of mitochondrial morphology and vulnerability to 
stress [8,33]. Moreover, it participates in 
adipogenesis by binding galectin-12, a protein 
required for adipogenic signalling and adipocyte 
differentiation in vitro [32]. In turn, hVps13D 
regulates interleukin-6 (IL-6) production and/or 
transport, since silencing of a gene encoding 
hVps13D in HeLa cells significantly increased the 
IL-6 levels in the medium in both non-stimulated and 
stimulated conditions [13]. To sum up, the hVps13 
proteins are apparently involved in many key 
cellular processes. Hence, disturbances in their 
functioning lead to severe disorders affecting 
various tissues. 
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Recent insights in Vps13 function from studies 
on Dictyostelium, Tetrahymena and Drosophila 
species 
The Vps13 proteins are not unique for 
humans but are evolutionary conserved in 
eukaryotic organisms. The members of Vps13 
family are found in yeast Saccharomyces cerevisiae 
[34], a ciliated protozoan Tetrahymena thermophila 
[35], a social amoeba Dictyostelium discoideum 
[28], insects [36], mouse [37] and others [1]. The 
high degree of conservation suggests that the 
functions of Vps13 family members are preserved 
during evolution and concern basic cellular 
processes. This fact encourages researchers to use 
model organisms to study Vps13 proteins as well as 
the mechanisms of their related diseases. 
In the amoeba D. discoideum, the absence 
of one of its six Vps13 homologues, called TipC (or 
DdVps13C), leads to an aberrant multicellular 
structure in development and defective sporulation, 
phenotypes observed in many autophagy mutants. 
Autophagic flux was impaired in the mutant cells, 
which consistently accumulated ubiquitin positive 
structures, probably representing protein 
aggregates [28]. Ubiquitinated proteins were also 
accumulated in a Drosophila melanogaster 
DmVps13 mutant [38] and α-synuclein-mediated 
neurodegeneration was increased in 
D. melanogaster retina lacking the same Vps13 
homologue [33]. The D. melanogaster protein has 
been co-fractioned with endosomal proteins and its 
absence resulted in reduced endocytosis [38,39]. 
The morphology and acidification of endosomal 
compartments were shown to be unaltered in a 
D. discoideum mutant lacking another Vps13 
homologue (DdVps13F), characterized by a slight 
delayed growth on Klebsiella pneumoniae lawns. 
This defect was mainly attributed to a defective 
intracellular killing of K. pneumoniae, as phagocytic 
internalisation was not significantly altered in that 
mutant after a short incubation with heat-inactivated 
K. pneumoniae or fluorescent latex beads [40]. 
However, in the tipC mutant of D. discoideum, the 
reduced phagocytosis was observed upon longer 
incubation times [28]. Another D. discoideum 
mutant, with vps13A knock-out, showed defective 
growth dependent on phagocytosis of Micrococcus 
luteus [40]. Moreover, phagocytosis was reduced 
and phagocytic digestion was delayed in T. 
thermophila lacking a Vps13 homologue [35], which 
was identified as a component of phagosomes in a 
mass spectrometry analysis [41] and shown to 
localize at the membrane of phagosomes [35]. 
Altogether, the study of functions of the Vps13 
proteins in these model organisms points to a role of 
Vps13 proteins in processes highly dependent on 
membranes, vesicle trafficking and lysosomal 
degradation pathways. It is well-known that a 
deficient degradative capacity of cells is involved in 
multiple human diseases, including the major 
neurodegenerative diseases, and thus it should be 
taken into account as a possible therapeutic target 
of hVPS13-related diseases. 
 
 
 
Yeast as a model to study Vps13 proteins and 
associated diseases 
The budding yeast S. cerevisiae is one of the 
most studied and best-characterized eukaryotic 
models. Its extensive use as a model organism to 
understand the intricacies of human diseases is 
motivated by the high evolutionary conservation of 
fundamental cellular processes with higher 
eukaryotes. Indeed, yeast encodes orthologues of 
many human disease genes and, conversely, some 
human genes can complement the defects caused 
by the lack of native yeast genes [42–45]. In 
addition, yeast is genetically tractable, has a short 
generation time, and is cheap and easy to culture. 
All these features place S. cerevisiae as a one of 
the most potent eukaryotic model organisms to 
study the molecular mechanisms underlying human 
diseases [46] and the effect of particular mutations 
on protein function. Yeast has proven its utility in the 
study of mitochondrial diseases [47], 
neurodegenerative disorders [48–50], inherited 
peripheral neuropathies [51] and other diseases 
[52]. Moreover, yeast is suitable for high-throughput 
screening approaches to identify drugs that may 
turn out to be effective in the treatment of human 
disorders [53,54]. 
Yeast possesses a single intron-less VPS13 
(YLL040C) gene encoding a Vps13 protein, which 
may execute many of the activities performed by 
different human hVps13 proteins. Consequently, 
functional complementation by other protein 
isoforms is not possible. This feature simplifies the 
study of the underlying mechanisms of Vps13 
associated disorders and the impact of disease 
causing mutations and, together with all the 
advantages described above, makes yeast a 
powerful and simple model to study the function of 
hVps13 proteins and associated diseases. 
 
Vps13 in yeast 
The Vps13 of S. cerevisiae is a large protein 
(358 kDa) peripherally associated with membranes 
[34]. Vps13 is most similar to human hVps13A [1] 
presenting a comparable domain structure: 
Chorein_N, VPS13 domain, VPS13_mid_rpt, 
SHR_BD (previously called DUF1162, domain of 
unknown function No. 1162) and VPS13_C (Fig.1A); 
according to the Pfam database 
(http://pfam.xfam.org) [1,35,55,56]. The ATG_C 
(Autophagy-related protein C-terminal domain) 
region was recognized in yeast Vps13 and human 
hVps13A [28], and using the HHpred program other 
authors revealed the presence of two ATG_C 
domains in yeast Vps13 – a full-length domain 
(amino acids (aa) 2921-3005) and a truncated one 
(aa 2845-2909), which overlap with the VPS13_C 
domain [57]. Moreover, the APT1 domain between 
SHR-BD and ATG_C was identified in both human 
hVps13A and yeast Vps13 (Fig.1A) [57]. An 
independent HHsearch at the C-terminal region of 
Vps13 revealed the presence of homology to the 
pleckstrin homology domains (PH), which are typical 
docking sites for phosphatidylinositol lipids [58], and 
homology to this domain was also found in hVps13A 
in our recent analysis using Phyre2 (K. Flis, 
unpublished result). Recently, using single-particle 
electron microscopic analysis of negatively stained 
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protein, an approximate 3D architecture of yeast 
Vps13 was visualized (Fig.1B) [59]. Vps13 is folded 
into a compact rod-shaped density (20×4 nm) with a 
flexible portion in its middle, a characteristic loop 
structure with internal diameter of ∼6 nm at one end 
and a hook-like density on the opposite end that can 
be found on the same or opposite site (Fig.1B) [59]; 
however, the position of N- and C-terminal regions 
in this structure is still unknown. Vps13 was very 
recently found to be a lipid-binding protein as it 
binds to phosphatidic acid (PA), mono- and 
diphosphorylated phosphatidylinositol derivatives 
(PIP and PIP2, respectively), lysophosphatidic acid 
(LPA) and, with very low affinity, to 
phosphatidylserine (PS) [59]. Interestingly, Vps13 
possesses at least four lipid-binding regions, which 
may independently bind to different phospholipids: 
the N terminus (aa 1-437) interacts with PA, 
PI(4,5)P2, and PI4P; the C terminus (aa 2905-3144) 
binds to PI(4,5)P2 [59]; the central SHR_BD domain 
containing region (aa 2158-2575) binds all 
phosphorylated phosphatidylinositol derivatives 
(PIPs), PA and lysophosphatidic acid (LPA); and the 
APT1 domain region (aa 2492-2844) interacts 
almost exclusively with PI3P (Fig.1A) [57].  
Yeast Vps13 is involved in cellular transport 
and was originally identiﬁed by its role in vesicular 
trafﬁcking between the Golgi apparatus and 
vacuole. The null mutant of VPS13 (vps13∆) 
exhibits mislocalization of the native vacuolar 
enzyme carboxypeptidase Y (CPY) and the 
proteases Pep4 and Prb1 to the cell surface 
[34,60,61]. Moreover, Vps13 is also required for 
Golgi-to-vacuole transport of an adaptor membrane 
protein Sna3 [57]. The vps13∆ mutant also shows 
disturbed retrograde transport from the late 
endosome (LE) to the Golgi apparatus and 
accelerated vacuolar degradation of the sorting 
receptor Vps10 [34]. Recently, it was reported that 
Vps13 is directly required for transport from the 
Golgi network to the LE compartment and for trans-
Golgi homotypic fusion [59]. Vps13 is also involved 
in the endocytic transport of lipids and proteins from 
the plasma membrane to vacuole, as determined by 
internalization of the lipophilic dye FM4-64 [57,62] 
and Can1 transporter [57]. Defects of vps13∆ in 
endosomal recycling of proteins were also reported 
[63]. 
Similar to hVps13A, Vps13 is involved in the 
regulation of the actin cytoskeleton network. Vps13 
was found among proteins captured in in vitro actin 
assembly assay using microbeads coated with 
nucleation promoting factor Las17 (yeast WASP) 
[64] and it binds actin in immunoprecipitation assays 
[57]. Moreover, the vps13∆ strain displays defects in 
actin cytoskeleton organization [57]. Additionally, it 
is worth mentioning that the internal diameter 
(∼6 nm) of the loop in Vps13 structure is similar to 
the diameter of an F-actin filament [59], further 
suggesting that Vps13 may directly interact and 
regulate the actin cytoskeleton network. 
The actin cytoskeleton is important for many 
processes based on membrane dynamics, such as 
endocytosis, retrograde transport [65,66] and that 
list also includes mitochondrial inheritance and 
integrity [67,68]. Therefore, it was not surprising 
that, similarly to hVps13C, yeast Vps13 was found 
to be involved in mitochondrial homeostasis. The 
vps13∆ cells show increased rate of nuclear transfer 
of mitochondrial DNA (mtDNA) indicating defects in 
mtDNA stability and mitochondrial integrity [69]. This 
could be also the reason for the increased rate of 
mitophagy that was observed in the vps13∆ strain 
[69]. 
Vps13 is also involved in sporulation, which 
is the yeast equivalent of gametogenesis [70]. 
During this process, four haploid nuclei are 
produced by meiosis and enveloped within a novel 
intracellular membrane called the prospore 
membrane. Sporulation efficiency is reduced 
~2,500-fold in vps13∆ [34], as a result of defects in 
the formation of prospore membranes, which are 
smaller and only about a quarter of them capture 
nuclei [71]. Upon sporulation, Vps13 translocates to 
the prospore membrane where it promotes 
expansion of the membrane and regulates its 
bending, being also required for cytokinesis [72]. 
The observed defects in vps13∆ during sporulation 
are probably associated with the reduced levels of 
PI(4,5)P2 and its precursor, PI4P, in the prospore 
membrane [72]. 
Initially, it was claimed that Vps13 localized 
to the cytoplasm and endosomes [73] and later to 
the prospore membrane [72]. Recently, it was 
demonstrated that Vps13 is also localized to the 
membrane contact sites (MCSs), where it may 
hypothetically regulate their formation or function 
(Fig.2) [69,74]. The MCSs are structures where two 
membranes are tethered in close apposition, but not 
fuse. These junctions allow the exchange of ions, 
metabolites and lipids between membranes and 
organelles [75]. Vps13 was found in mitochondria 
and vacuole contacts called vacuole and 
mitochondria patch (vCLAMP), between vacuole 
and the ER-derived nuclear envelope–vacuole 
junction (NVJ) [69,74], and at the interface between 
the endosomes and mitochondria (IEM) [69], 
depending on the carbon source. Deletion of VPS13 
is synthetically lethal in combination with mutations 
of MMM1, encoding an integral ER membrane 
protein that is a subunit of the ER-mitochondria 
encounter structure (ERMES) complex, tethering the 
ER and mitochondria [69,74]. Also, dominant 
mutations in VPS13 suppress all known ERMES 
complex-deficient phenotypes, probably by 
increasing the formation or function of vCLAMP [74]. 
This role in MCS is well-matched with the current 
reports presenting that purified Vps13 exhibits 
ATP-stimulated binding to yeast membranes and 
interacts with various membrane lipids, as described 
above [59]. Moreover, association of Vps13 with 
lipids is important for its localization, as microscopy 
studies showed that Vps13-GFP localization is 
altered in strains with decreased PI3P level due to 
the lack of Vps30 and Vps38 subunits of the 
phosphatidylinositol 3-kinase (PI3K) complex; 
Vps13-GFP is accumulated in large perivacuolar 
membrane compartments of endocytic origin [57]. 
As the MCSs between particular membranes 
regulate the dynamics and functions of organelles 
through the trafficking of various molecules, it is 
possible that the observed disturbances in vesicular 
transport, sporulation and mtDNA stability in the 
vps13∆ cells are a result of changes in MCSs 
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formation or function. Thus, it is not surprising that 
the depletion of Vps13 results in such pleiotropic 
effects. 
Summarizing, the single yeast Vps13 protein 
seems to participate in multiple cellular processes 
including membrane and protein trafficking, actin 
cytoskeleton organization and mitochondrial 
stability. It binds to several membranes and is able 
to interact with multiple phospholipids through at 
least four regions dispersed from N to C terminus. It 
also participates in the formation or function of 
multiple MCSs. However, the molecular mechanism 
by which Vps13 regulates such a variety of 
processes is still unknown. It is possible that a 
single property, such as the role in MCSs, may 
impact and explain the defects observed by the loss 
of Vps13, or alternatively, Vps13 may display 
different molecular functions associated perhaps 
with the different conserved domains. 
 
Exploring the yeast Vps13 to decipher 
ChAc mechanisms 
As mentioned above, mutations in human 
VPS13 genes are involved in several human 
diseases and yeast Vps13 may provide a valuable 
research model to study the molecular 
underpinnings on the pathological mechanisms. 
With reference to hVPS13A mutations leading to 
ChAc, most of the described mutations cause a 
premature STOP codon (nonsense mutations) or a 
reading frame shift (frameshift mutations, i.e. 
insertions or deletions) and are relatively easy to 
interpret, since they result in a truncated protein. 
However, missense mutations resulting in amino 
acid substitutions in hVps13A have also been 
described and they require in-depth studies. So far, 
five yeast VPS13 mutations corresponding to ChAc-
associated hVPS13A missense mutations were 
investigated: L66P, C89K, L1107P, Y2702C and 
I2749R (see Table 2 for a list of human missense 
mutations). Intriguingly, the effect of each of those 
mutations on Vps13 functioning in yeast cells was 
different suggesting that a universal mechanism 
leading to ChAc disease may not exist. No 
phenotypes were observed for vps13-Y2702C 
variant, indicating that this mutation does not alter 
the function of the yeast protein in the processes 
tested [69]. In contrast, the vps13-L1107P mutant 
strain shows a defect in CPY sorting and mmm1∆ 
complementation. Moreover, vps13-L66P and 
vps13-C89K were also synthetically lethal with 
mmm1∆, demonstrating the inability of these 
variants to compensate for the loss of ERMES [69]. 
Finally, the vps13-I2749R yeast variant was inactive 
in all processes tested, suggesting a loss of function 
[57] (see Table 2 for a description of the associated 
phenotypes to these mutations). Importantly, the 
I2749R substitution, which is located in the APT1 
domain, diminished binding of Vps13 fragment to 
PI3P, suggesting that this binding is essential to all 
Vps13 functions [57]. Based on the homology of 
Vps13 to hVps13A and these recent findings, a 
model suggesting a possible mechanism of ChAc 
pathogenesis was proposed where I2771R 
substitution may diminish the binding of APT1 
domain of hVps13A to PI3P-enriched membranes 
affecting the hVps13A localization and/or function 
[57]. 
 
Conclusions and future perspectives 
The huge contribution of simple model 
organisms for the state of art knowledge on the 
molecular and cellular mechanisms underlying many 
human diseases is undeniable. Because 
S. cerevisiae is the simplest eukaryotic organism 
surrounded by a plethora of available genetic and 
molecular tools, the yeast-based models have a 
prominent role as living test tubes to address 
several fundamental aspects associated with 
pathological processes of many diseases. Although 
yeast has greatly contributed to the study of 
neurodegenerative disorders, such as Alzheimer’s 
and Parkinson’s diseases [50,76], its exploitation for 
the study of rare genetic diseases is still limited. The 
studies summarized in this review are a testimony of 
the potential of yeast models to unveil the intricacies 
of human Vps13-related diseases, particularly 
ChAc. Furthermore, ChAc molecular targets 
amenable for therapeutic intervention could also be 
identified using yeast as a powerful toolbox for high-
throughput genetic screenings. In addition, high-
throughput assay formats could also be explored as 
primary drug-screening platforms to filter for 
natural/chemical small molecules with cytoprotective 
action towards ChAc pathological processes, 
addressing the lack of effective drugs as an 
important knowledge-gap on ChAc research. 
Other models, such as the social amoeba 
D. discoideum can complement the studies in yeast. 
In several aspects, this organism is more similar to 
animal cells than to fungi for processes such as 
phagocytosis, cell motility, development, and the 
lysosomal and autophagic pathways [77]. The 
presence of 6 different vps13 genes and the 
apparently non-similar phenotypes associated with 
their mutations in D. discoideum suggest that in 
multicellular organisms, such as humans, there may 
have been a specialization of functions that could 
facilitate the study of specific processes.  
In conclusion, S. cerevisiae and other lower 
eukaryotic organisms such as D. discoideum 
represent an invaluable tool for the study of the 
molecular function of Vps13 proteins and a better 
understanding of the diverse set of processes 
potentially affected in the associated human 
diseases and they hopefully will open up new 
avenues for future treatments.  
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Figure Legends and Tables  
 
FIGURE 1. Structure of both yeast Vps13 and human Vps13A proteins. 
A. The schematic representation of domain architecture of Vps13 proteins based on Pfam database records, 
recent results and unpublished analysis done using the Phyre2 software  (http://www.sbg.bio.ic.ac.uk/phyre2) 
[78]. The regions of yeast Vps13 with in vitro recognized lipid-binding ability are marked as horizontal bars with 
lipids listed: LPA, lysophosphatidic acid; PA, phosphatidic acid; PI, phosphatidylinositol; PIPs, phosphorylated PI 
derivatives; PI3P, PI3-phosphate; PI4P, PI4-phosphate; PI5P, PI5-phosphate; PI(3,5)P2, PI(3,5)-bisphosphate; 
PI(4,5)P2, PI(4,5)-bisphosphate; PS, phosphatidylserine. 
B. Two examples of 3D reconstructions at ~30Å level of TAP-tag purified Vps13 obtained from particle projections 
based on electron microscopy images of negatively stained protein. Scale bar, 20 nm. Figure reprinted with small 
modifications, with publisher (Rockefeller University Press) permission, from original paper [59] (© 2017 De M. et 
al. Journal of Cell Biology; 216:425–439. doi: 10.1083/jcb.201606078). 
 
 
FIGURE 2. Localization of Vps13-GFP and involvement of Vps13 in various processes in yeast cells. The 
intracellular sites of Vps13-GFP localization are schematically shown in tones of green and Vps13 relevance for 
particular processes is indicated. Abbreviations for intracellular junctions: NVJ, ER-derived nuclear envelope-
vacuole junctions; vCLAMP, vacuole and mitochondria patch; IEM, interface between the endosomes and 
mitochondria; ERMES, endoplasmic reticulum-mitochondria encounter structure. Components of a cell: CW, cell 
wall; EE, early endosome; ER, endoplasmic reticulum; LE, late endosome; Mito, mitochondrion; PM, plasma 
membrane. 
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TABLE 1. Mutation types found in the hVPS13 genes1 
Point mutations in coding regions Splicing Small rearrangements  Gross rearrangements Total2 Missense Nonsense Total2 SNP3 Deletions Insertions/Duplications Indels  Deletions Insertions/Duplications Complex  
VPS13A (Aliases: CHAC, CHOREIN; Chromosomal location: 9q21.2) 
Chorea-acanthocytosis (108) 
Schizophrenia (1) 
9 26 35 31 21 37 6 1  6 1 2 109 
VPS13B (Aliases: CHS1, COH1; Chromosomal location: 8q22.2) 
Cohen syndrome (165) 
Cohen syndrome, cutis verticis gyrata and sensorineural deafness (1) 
Cohen syndrome with autistic-like features (1) 
Autism (7) 
Intellectual disability (3) 
Intellectual disability and microcephaly (1)  
Microcephaly, mild cortical atrophy (1) 
Malformations of cortical development (2) 
Neutropaenia with retinopathy (2) 
Retinal dystrophy (1) 
17 (16)4 37 54 72 20 42 (43)4 22 6  33 6 1 184 
VPS13C (Alias: PARK23; Chromosomal location: 15q22.2) 
Parkinsonism (5) 
Schizophrenia (1) 
 1 1  2 2 1      6 
VPS13D (No aliases found; Chromosomal location: 1p36.22) 
Schizophrenia (1) 
1  1          1 
1 Data compilation according to the Human Gene Mutation Database (HGMD; http://www.hgmd.cf.ac.uk/ac/index.php) ver. Professional 2016.4; below the gene 
names, the diseases are listed with the numbers of associated mutations indicated in the parentheses.  
2 Total numbers of known point mutations without SNPs. 
3 Nucleotide sequence variations according to the Single Nucleotide Polymorphism Database (dsSNP; https://www.ncbi.nlm.nih.gov/SNP/) causing amino acid 
substitutions, which are not connected yet to any disease/phenotype.   
4 One of mutations, i.e. M1I, is a missense mutation, but from the physiological point of view should be considered as a small deletion, since it causes start of 
translation from the second in-frame ATG codon resulting in 10-aa shortening of the protein at the N terminus.  
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TABLE 2. Conversion table of human Vps13 amino acid substitutions to yeast equivalents  
hVps13A Yeast Vps13 Domain Resulting yeast phenotype
1 Reference 
 
 
 
L67P L66P Chorein_N – Synthetically lethal with mmm1∆ [69] 
 
 
I90K C89K Chorein_N – Synthetically lethal with mmm1∆ [69]  
A1095P L1107P Region between 
Vps13_mid_rpt 
– CPY secretion (→ defect of transport to the vacuole)  
– Synthetically lethal with mmm1∆ [69] 
 
 
 
Y2721C 
 
Y2702C 
 
APT1 
 
– None found 
 
[69] 
 
 
I2771R I2749R APT1 – Diminished binding ability of Vps13 to PI3P 
– Actin cytoskeleton disturbances 
– CPY secretion (→ defect of transport to the vacuole) 
– FM4-64 internalization (→ endocytosis defect) 
– Canavanine hypersensitivity (CanS; → endocytosis defect) 
– Sna3 Golgi-to-vacuole transport delay (→ inefficient MVB sorting)  
– Synthetically lethal with mmm1∆  
– Sporulation defect 
 
[57] 
 
 
 
 
 
 
 
1 MVB, multivesicular body 
 
